This is a working overview of Certificate of analysis, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-04-07. Anything still debated is marked as such rather than presented as settled.
Dihexa is a synthetic peptide that has been examined in laboratory and animal research. Its design is based on angiotensin IV, a naturally occurring peptide fragment produced in the body. The short name dihexa appears in scientific papers and online discussions, while the full chemical name describes a modified peptide chain. It is not a vitamin, mineral, or plant-derived compound. Suppliers typically present it as a research chemical rather than an approved medicine.
The full name often given is N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. This name indicates a chain containing tyrosine, isoleucine, and a six-carbon amino acid derivative. Databases list a CAS Registry Number and a molecular formula for the compound. The peptide is small compared with proteins, and its structure allows it to be studied in cell cultures and animal models. Exact identity depends on the supplier's synthesis and purification process. Minor impurities can remain after synthesis.
Chemically, dihexa belongs to a broader group of angiotensin IV analogs. Researchers have modified the natural peptide to alter stability, binding, or distribution. Such changes can affect how the molecule behaves in experiments. The parent peptide angiotensin IV is involved in various physiological processes, but the modified analog is not identical to it. Public summaries sometimes blur the distinction between the natural fragment and the synthetic research compound. This distinction matters when interpreting study results.
Dissolution depends on the peptide’s salt form, purity, and the chosen solvent. Dimethyl sulfoxide is commonly used to prepare concentrated stock solutions, while aqueous buffers may show limited solubility. Sonication or gentle warming can sometimes aid dissolution, but excessive heat may promote degradation. Once in solution, the material is generally kept cold and protected from light. Researchers should verify solubility for each lot rather than assuming uniform behavior across suppliers.
Quality control usually combines reverse-phase high-performance liquid chromatography with mass spectrometry. Chromatography estimates purity and detects related impurities, while mass spectrometry supports molecular identity. Nuclear magnetic resonance can provide additional structural confirmation when needed. Stability data for dihexa are limited, and degradation pathways may depend on pH, temperature, and moisture. Open questions include long-term stability in different formulations and the effect of repeated freeze-thaw cycles on measured purity. Such tests help confirm that a batch matches its label before use.
In laboratory settings, dihexa is typically handled as a lyophilized peptide powder. Appropriate personal protective equipment and a ventilated workspace are standard practices for weighing and transferring research chemicals. Because the compound lacks regulatory approval for clinical use, it should not be given to people. Institutional safety rules and local regulations govern its acquisition, storage, and disposal. Suppliers often provide a certificate of analysis that lists purity, identity, and batch-specific handling notes.
| Property | Value | Notes |
|---|---|---|
| Common name | Dihexa | Shorthand used in research literature and supplier catalogs. |
| CAS Registry Number | 1401708-83-5 | Identifier assigned to the synthetic peptide. |
| Molecular formula | C27H44N4O5 | Reported formula; verify with a certificate of analysis. |
| Appearance | White to off-white powder | Typical form for lyophilized research peptides. |
| Typical storage | −20 °C or below, desiccated | Common condition for peptide stability. |
The proposed mechanism of dihexa involves activation of hepatocyte growth factor and its receptor, c-Met. In cell models, this signaling pathway is associated with dendritic spine formation and synaptic reorganization. Dihexa is described as a stabilized analog of angiotensin IV, which also interacts with related systems. However, the precise binding profile and downstream effects remain incompletely characterized. Most mechanistic evidence comes from in vitro assays and rodent studies rather than human trials.
Laboratory characterization of dihexa typically relies on reverse-phase high-performance liquid chromatography for purity and mass spectrometry for identity. These methods are standard for synthetic peptides and help distinguish the target compound from related impurities or degradation products. Because dihexa is a small peptide-like molecule, it may be susceptible to hydrolysis under certain conditions. Storage recommendations generally emphasize low temperature, dryness, and protection from light. Analytical certificates from suppliers vary in detail, so independent verification can be important for research use.
Reported effects of dihexa are often described in terms of synaptogenesis, a process by which neurons form new synaptic connections. This concept is biologically plausible but difficult to measure directly in living humans. Animal behavioral tests can suggest memory or learning changes, yet such tests have limitations and may not translate to people. The literature includes conflicting or incomplete findings, and some studies are small. As a result, the mechanism remains a subject of investigation rather than a settled explanation.
Development of dihexa followed from studies on angiotensin IV analogs and their effects on learning and memory. Researchers sought compounds with improved metabolic stability and brain penetration compared with natural peptides. In preclinical reports, dihexa was associated with changes in synaptic connectivity and performance on spatial tasks. These findings generated interest in its potential as a cognitive research tool. The work remains largely preclinical, and independent replication has been limited.
Regulatory and commercial contexts differ from clinical medicine. Dihexa is not approved as a drug by major agencies, and no published human trials establish its safety or efficacy. It is often sold as a research chemical labeled for laboratory use only. Suppliers may provide certificates of analysis, but purity and identity depend on the specific batch. Legal status varies by country and may treat such compounds as unapproved substances for human consumption.
Dihexa is a synthetic peptidomimetic derived from angiotensin IV, a naturally occurring peptide fragment. It was created as a research compound to explore central nervous system signaling rather than as an approved therapeutic. Early work described it as a small, orally available molecule in rodent studies. Its structure combines tyrosine, isoleucine, and aminohexanoic acid components with a hexanoic acid cap. The compound is commonly referred to by the research code PNB-0408.
==== Azetidine based compounds ==== Informations for this group of inhibitors are quite restricted. Azetidine-based DPP-4 inhibitors can roughly be grouped into three main subcategories: 2-cyanoazetidines, 3-fluoroazetidines, and 2-ketoazetidines. The most potent ketoazetidines and cyanoazetidines have large hydrophobic amino acid groups bound to the azetidine nitrogen and are active below 100nM.
=== Subdivision === Viola is a large genus that has traditionally been treated in sections. One of these was that of Gingins (1823), based on stigma morphology, with five sections (Nomimium, Dischidium, Chamaemelanium, Melanium, Leptidium). The extensive taxonomic studies of Wilhelm Becker, culminating in his 1925 conspectus, resulted in 14 sections and many infrasectional groups. The largest and most diverse, being section Viola, with 17 subsections. In addition to subsections, series were also described. Alternatively, some authors have preferred to subdivide the genus into subgenera. Subsequent treatments were by Gershoy (1934) and Clausen (1964), using subsections and series. These were all based on morphological characteristics. Subsequent studies using molecular phylogenetic methods, such as that of Ballard et al. (1998) have shown that many of these traditional divisions are not monophyletic, the problem being related to a high degree of hybridization. In particular section Nomimium was dismembered into several new sections and transferring part of it to section Viola. Section Viola s. lat. is represented by four sections, Viola sensu stricto, Plagiostigma s. str., Nosphinium sensu lato. and the V. spathulata group. In that analysis, the S American sections appear to be the basal groups, starting with Rubellium, then Leptidium. However, the exact phylogenetic relationships remain unresolved, as a consequence many different taxonomic nomenclatures are in use, including groupings referred to as Grex. Marcussen et al.
== Production == The Netflix docuseries Diagnosis was a production created and produced by Netflix and The New York Times together. It draws from the column written by Dr. Lisa Sanders, who seeks to help patients whose conditions have not been diagnosed and resist treatment. For these episodes, Sanders seeks to crowdsource diagnoses and treatments. She published each case in her column, Diagnosis, in The New York Times and invited readers to help solve each medical mystery. The emphasis is on the process of finding answers and patients are treated with respect. Doctors and patients from around the world have responded. Dr. Sanders has been able to provide each patient with a diagnosis of their case, sometimes leading to treatment, and also giving them a sense of belonging and hope. Each patient’s journey through their diagnosis is shown in a 40-minute episode, where viewers can see the progression of a life-changing movement. The result from this project was a seven-episode docuseries. Diagnosis was released on August 16, 2019, on Netflix.
Investors at several venture capital firms, including executives at Peter Thiel's Founders Fund, Union Square Ventures and Coatue Management urged their portfolio companies to withdraw their deposits from the bank, with Founders Fund withdrawing all of its funds from the bank by the morning of March 9. By the close of business that day, customers had withdrawn $42 billion, leaving the bank with a negative cash balance of about $958 million. Among the financial services companies receiving money from SVB customers were Brex, JPMorgan Chase, Morgan Stanley and First Republic Bank. The value of SVB's shares plummeted until a trading halt was implemented on the morning of March 10. On February 27, SVB Financial Group CEO Greg Becker sold 12,451 shares of company stock, worth $3.6 million, through an executive trading plan that he filed with the SEC under Rule 10b5-1 on January 26. The rule has been criticized as a loophole allowing for insider trading. Beginning April 1, the SEC will require a minimum 90-day cooling period for most executive trading plans.
Sources: en.wikipedia.org
=== Phase 3 === Botulinum toxin A (AboBoNT-A; AbobotulinumtoxinA; Alluzience; Azzalure; BoNT-A; BTX-A; Dysport; Reloxin) – acetylcholine release inhibitor and neuromuscular blocking agent – migraine [1] Botulinum toxin A (Bocouture; Incobotulinum toxin A; NT-201; Vibe/Xeomin; ViXe; Xeomeen; Xeomin; Zeomaine) – acetylcholine release inhibitor and neuromuscular blocking agent – migraine [2] Eptinezumab (ALD-403; Lu-AG09221; Vyepti) – monoclonal antibody against calcitonin gene-related peptide (CGRP) – cluster headache [3] Naproxen/rizatriptan (rizatriptan/naproxen) – combination of naproxen (COX inhibitor/NSAID) and rizatriptan (triptan) – migraine [4] Promethazine/sumatriptan (CL-H1T) – combination of promethazine (anthistamine, anticholinergic, other actions) and sumatriptan (triptan) – migraine [5]
=== Public transportation statistics === The average amount of time people spend commuting with public transit in Turin (for example, to and from work) on a weekday is 65 minutes. 14% of public transit riders ride for more than 2 hours every day. The average time spent waiting at a stop or station for public transit is 14 minutes, while 19% of riders wait for over 20 minutes on average every day. The average distance people usually ride in a single trip with public transit is 5.9 km (3.7 mi), while 9% travel more than 12 km (7.5 mi) in a single direction.
=== Acidity === The phosphate groups of DNA give it similar acidic properties to phosphoric acid and it can be considered as a strong acid. It will be fully ionized at a normal cellular pH, releasing protons which leave behind negative charges on the phosphate groups. These negative charges protect DNA from breakdown by hydrolysis by repelling nucleophiles which could hydrolyze it.
Sources: en.wikipedia.org
In February 2007, a 2003 sex tape made by sister Kim Kardashian and her former boyfriend Ray J, Kim Kardashian, Superstar, was leaked, which contributed to the family's rise in popularity. Later that year, Khloé; her mother Kris; her stepparent Caitlyn; her siblings Kourtney, Kim, and Rob; and half-sisters Kendall and Kylie were commissioned to star in the reality television series Keeping Up with the Kardashians. The series and her sister Kim's popularity led to the Kardashians being able to cash in by endorsing products. These include waist-slimming pants, beauty products and Coca-Cola, for which they are paid (as of 2016) $75,000 per post on Instagram, Facebook and Twitter. The series proved successful for E!, the network on which it is broadcast, and has led to the creations of spin-offs including Kourtney and Khloé Take Miami and Khloé & Lamar.
=== Medicaid overbilling === A fraud investigation by the United States Department of Justice began in 2000 when allegations were brought in two separate lawsuits filed by whistleblowers under the False Claims Act. They alleged that Merck failed to pay proper rebates to Medicaid and other health care programs and paid illegal remuneration to health care providers. On February 7, 2008, Merck agreed to pay more than $650 million to settle charges that it routinely overbilled Medicaid for its most popular medicines. The settlement was one of the largest pharmaceutical settlements in history. The federal government received more than $360 million, plus 49 states and Washington, DC, received over $290 million. One whistleblower received a $68 million reward. Merck made the settlement without an admission of liability or wrongdoing.
=== Dendritic secretion === Supraoptic neurons have typically 1-3 large dendrites, most of which projecting ventrally to form a mat of process at the base of the nucleus, called the ventral glial lamina. The dendrites receive most of the synaptic terminals from afferent neurons that regulate the supraoptic neurons, but neuronal dendrites are often actively involved in information processing, rather than being simply passive receivers of information. The dendrites of supraoptic neurons contain large numbers of neurosecretory vesicles that contain oxytocin and vasopressin, and they can be released from the dendrites by exocytosis. The oxytocin and vasopressin that is released at the posterior pituitary gland enters the blood, and cannot re-enter the brain because the blood–brain barrier does not allow oxytocin and vasopressin through, but the oxytocin and vasopressin that is released from dendrites acts within the brain. Oxytocin neurons themselves express oxytocin receptors, and vasopressin neurons express vasopressin receptors, so dendritically released peptides "autoregulate" the supraoptic neurons. Francoise Moos and Phillipe Richard first showed that the autoregulatory action of oxytocin is important for the milk-ejection reflex. These peptides have relatively long half-lives in the brain (about 20 minutes in the CSF), and they are released in large amounts in the supraoptic nucleus, and so they are available to diffuse through the extracellular spaces of the brain to act at distant targets.
Bophuthatswana ran a now-defunct television station called Bop TV. Bop TV was also available in some townships like Soweto, for Tswana people (who were ostensibly citizens of Bophuthatswana), but the signal was also watched by white South Africans seeking a more entertaining alternative to the SABC.
Sources: en.wikipedia.org
Dihexa is a synthetic peptide modeled on angiotensin IV. It is used in laboratory and animal research, not as an approved medicine. Human effects remain poorly characterized.
It is produced by chemical synthesis, not extracted from plants or animals. Its design is based on a naturally occurring peptide fragment. Suppliers sell it as a research chemical.
No, dihexa is a modified analog of angiotensin IV. The two share a structural relationship but differ in chemical details. Research on one does not automatically apply to the other.
Typical storage is at -20 °C in a desiccated container protected from light. Repeated freeze-thaw cycles are usually minimized to reduce degradation. Specific conditions should follow the supplier’s documentation.